🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

RecruitingPhase 4Ages 18 Years - anyAllUnity Health Toronto
NCT07017270 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 18 2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days 3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin. 4. Ability to provided informed consent or through their substitute decision maker Exclusion Criteria: 1. Type 1 DM 2. Use of a GLP-1-RA within 30 days prior to screening 3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening) 4. Confirmed pregnancy, women of childbearing potential 5. Known hypersensitivity to GLP-1-RA 6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months 7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA
💊

What it tests

  • Semaglutide Pen
📍

Where

2 sites
Unity Health Toronto
Toronto, Canada
Unity Health Toronto
Toronto, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy